MXCT vs PSNL

For growth investors, MaxCyte, Inc.

(MXCT) is the stronger pick with -14. 5% revenue growth year-over-year, versus -100. 0% for Personalis, Inc. (PSNL). Analysts rate Personalis, Inc. (PSNL) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Personalis, Inc.

(PSNL) delivered a total return of -73. 7%, compared to -94. 9% for MaxCyte, Inc. (MXCT). Over 10 years, the gap is even starker: PSNL returned -79. 0% versus MXCT's -94. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), MaxCyte, Inc.

(MXCT) is the lower-risk stock at 1. 44β versus Personalis, Inc. 's 2. 75β — meaning PSNL is approximately 91% more volatile than MXCT relative to the S&P 500. On balance sheet safety, MaxCyte, Inc. (MXCT) carries a lower debt/equity ratio of 10% versus 12% for Personalis, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), MaxCyte, Inc.

(MXCT) is pulling ahead at -14. 5% versus -100. 0% for Personalis, Inc. (PSNL). On earnings-per-share growth, the picture is similar: Personalis, Inc. grew EPS 33. 6% year-over-year, compared to -7. 7% for MaxCyte, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

MaxCyte, Inc.

(MXCT) is the more profitable company, earning -135. 1% net margin versus -194. 8% for Personalis, Inc. — meaning it keeps -135. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MXCT leads at -138. 3% versus -209. 0% for PSNL. At the gross margin level — before operating expenses — MXCT leads at 81. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, MaxCyte, Inc.

(MXCT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Personalis, Inc. (PSNL) carries a higher beta of 2. 75 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MXCT: -94. 9%, PSNL: -79. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.